Pulmonary Sarcoidosis, Stage I
A 38-year-old woman has bilateral hilar shadows on a screening chest radiograph. She has an occasional dry cough but no dyspnoea, fever, weight loss, or eye symptoms. Spirometry and diffusing capacity are normal. CT confirms bilateral hilar lymphadenopathy with clear parenchyma, and lymph node biopsy shows non-caseating granulomas with negative stains and cultures for mycobacteria and fungi. Which of the following is the most appropriate next step in management?
- A.Start anti-tuberculosis therapy
- B.Start oral prednisone
- C.Start azithromycin
- D.Observation with periodic reassessmentCorrect
Explanation
Bilateral hilar lymphadenopathy with clear lung parenchyma and biopsy-proven non-caseating granulomas is stage I pulmonary sarcoidosis. Stage I disease remits spontaneously in 60 to 90 percent of patients within 2 to 3 years, so an asymptomatic patient with normal lung function needs no drug therapy, only observation with clinical review, spirometry, and imaging every 3 to 6 months. Corticosteroids carry substantial cumulative toxicity, including weight gain, hyperglycaemia, osteoporosis, and infection risk, and starting them in asymptomatic stage I disease has never been shown to alter the natural history or prevent fibrosis. Treatment is reserved for progressive or symptomatic pulmonary disease with declining lung function, or for serious extrapulmonary involvement such as cardiac, neurological, ocular, or renal sarcoidosis, and for hypercalcaemia caused by extrarenal 1-alpha-hydroxylase activity in granulomas. Anti-tuberculosis therapy would be appropriate for caseating granulomas with positive acid-fast staining or culture, and the biopsy explicitly shows non-caseating granulomas with negative mycobacterial studies. Azithromycin has no role in sarcoidosis and does not treat granulomatous inflammation. Initial evaluation should still include serum calcium, renal and liver function, an electrocardiogram to screen for conduction disease, and a formal ophthalmological examination for asymptomatic uveitis, since occult cardiac and eye involvement would change management. Serum angiotensin-converting enzyme is neither sensitive nor specific enough to guide diagnosis or treatment decisions.
Why each option
- A.
- Anti-tuberculosis therapy requires evidence of mycobacterial infection; the granulomas here are non-caseating with negative stains and cultures.
- B.
- Systemic corticosteroids are reserved for symptomatic or progressive pulmonary disease or serious extrapulmonary involvement and carry considerable toxicity.
- C.
- Azithromycin treats bacterial infection and has no effect on granulomatous inflammation in sarcoidosis.
- D.
- Correct. Asymptomatic stage I sarcoidosis with normal lung function remits spontaneously in most patients and requires only surveillance.
Reference: ATS Clinical Practice Guideline on the Diagnosis and Detection of Sarcoidosis, 2020; ERS Guideline on Treatment of Sarcoidosis, 2021
This is one of 3,306 questions in the MedBoardSA SMLE bank, with timed test mode, tutor mode, and progress tracking by topic.
Practise the full bank